Clinical Trial Update: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125) [Phase 3]

View source ↗

Summary

Phase 3 HERMES study evaluated roflumilast's effect on exacerbation rate in chronic obstructive pulmonary disease. Results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2011-05-19